Information Provided By: 
Fly News Breaks for April 4, 2016
EW
Apr 4, 2016 | 07:58 EDT
As previously reported, BTIG upgraded Edwards Lifesciences to Buy from Neutral with a $115 price target. Analyst Sean Lavin expects S3 superiority to drive use, to lead to an immediate intermediate FDA approval, and to likely expand the label to all-comers. Lavin feels it is unethical to offer more invasive surgery to healthier patents when THVs very likely offer better survival and fewer strokes in these patients and expects doctors to push for use in borderline low-risk patients also.
News For EW From the Last 2 Days
There are no results for your query EW
